195. ヌーナン症候群 Noonan syndrome Clinical trials / Disease details

臨床試験数 : 14 / 薬物数 : 15 - (DrugBank : 5) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 9

diseases per page:

Showing 1 to 10 of 14 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03435627 (ClinicalTrials.gov)	February 26, 2018	31/1/2018	Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome ...	Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome ...	Genetic Disorder;Noonan Syndrome	Drug: Somatropin	Novo Nordisk A/S	NULL	Completed	3 Years	N/A	All	71		Japan
2	EUCTR2016-005022-10-DE (EUCTR)	13/02/2018	09/11/2017	Improvement of synaptic plasticity and cognitive function in RAS pathway disorders	Improvement of synaptic plasticity and cognitive function in RAS pathway disorders	Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029 ...	Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Nam ...	Technische Universität München, Fakultät für Medizin	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Germany
3	NCT02713945 (ClinicalTrials.gov)	January 25, 2017	9/3/2016	Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan ...	Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Childre ...	Noonan Syndrome	Drug: Simvastatin;Drug: Placebo	University Hospital, Toulouse	NULL	Recruiting	6 Years	16 Years	All	62	Phase 3	France
4	EUCTR2016-000647-14-FR (EUCTR)	23/05/2016	30/03/2016	Treatment with simvastatin of growth and bone abnormalities in children with Noonan syndrome	Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in childre ...	Noonan syndrome;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]	Trade Name: Simvastatin Product Name: Simvastatin	University Hospital Toulouse	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	62	Phase 3	France
5	NCT02383316 (ClinicalTrials.gov)	January 2015	23/12/2014	Study of Metabolic Modifications in Children With Noonan Syndrome	Study of Metabolic Modifications in Children With Noonan Syndrome	Child Syndrome	Other: Oral Glucose tolerance test	University Hospital, Toulouse	NULL	Completed	7 Years	18 Years	All	20	N/A	France
6	NCT01927861 (ClinicalTrials.gov)	August 19, 2013	20/8/2013	Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature ...	A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-lab ...	Genetic Disorder;Noonan Syndrome	Drug: somatropin	Novo Nordisk A/S	NULL	Completed	3 Years	10 Years	All	51	Phase 3	Japan
7	NCT01556568 (ClinicalTrials.gov)	February 2012	15/3/2012	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan SyndromeHypertrophic ...	An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 ...	Cardiomegaly	Drug: MEK162	Array Biopharma, now a wholly owned subsidiary of Pfizer	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2	United States;United Kingdom
8	EUCTR2011-003392-10-GB (EUCTR)	23/01/2012	24/08/2011	A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that e ...	An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 ...	Noonan syndromehypertrophic cardiomyopathy MedDRA version: 14.1;Level: PT;Classification code 100297 ...	Product Code: MEK162	Novartis Pharma Services AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	22		United Kingdom;United States
9	NCT01529944 (ClinicalTrials.gov)	September 2008	2/1/2012	Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO ...	Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial	Genetic Disorder;Noonan Syndrome	Drug: somatropin	Novo Nordisk A/S	NULL	Completed	N/A	N/A	Both	22	Phase 3	Sweden
10	NCT00351221 (ClinicalTrials.gov)	May 2006	11/7/2006	Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like G ...	A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Effi ...	Noonan Syndrome	Drug: rhIGF-1/rhIGFBP-3	Insmed Incorporated	NULL	Terminated	2 Years	16 Years	Both	24	Phase 2	United States

First Previous1 2Next Last